NCT03761095View on ClinicalTrials.gov

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

February 5, 2024

Study Completion Date

February 5, 2024

Conditions
Leiomyosarcoma
Interventions
DRUG

Unesbulin

Unesbulin will be administered as per the dose and schedule specified in the arm.

DRUG

Dacarbazine

Dacarbazine will be administered as per the dose and schedule specified in the arm.

Trial Locations (4)

10032

Columbia University Medical Center, New York

21287

John Hopkins, Baltimore

32204

Mayo Clinic Florida, Jacksonville

63110

Washington University Medical Campus, St Louis

Sponsors

Lead Sponsor

PTC Therapeutics
All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY

NCT03761095 - A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) | Biotech Hunter | Biotech Hunter